Follow the people · Insider
Teresa Marie Bitetti
Teresa Marie Bitetti files insider transactions with the SEC as a president, obu of Takeda Pharmaceutical Co (TAK). We hold 1 disclosed purchase or sale filed since 16 October 2023, 1 of them in the last 90 days.
- Files forTAK
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure12 August 2026
Positions held
3 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 27 April 2026 — 10 August 2026President, OBU · Takeda Pharmaceutical Co (TAK)3 Form 4 lines · source: SEC Form 4
- Filed 31 March 2025 — 11 June 2026Director · Aura Biosciences (AURA)4 Form 4 lines · source: SEC Form 4
- Filed 16 October 2023 — 4 June 2024Director · Fusion Pharmaceuticals (FUSN)2 Form 4 lines · source: SEC Form 4
Everything they disclosed
9 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 50,012 shares of Takeda Pharmaceutical CoSEC Form 412 August 2026American Depositary Shares · traded 10 August 2026 · filed 12 August 2026
- was granted 43,886 shares of Takeda Pharmaceutical CoSEC Form 46 July 2026American Depositary Shares · traded 1 July 2026 · filed 6 July 2026
- was granted 15,000 shares of Aura BiosciencesSEC Form 415 June 2026Common Stock · traded 11 June 2026 · filed 15 June 2026
- was granted 30,000 shares of Aura Biosciences (a derivative holding)SEC Form 415 June 2026Stock Option (Right to Buy) · traded 11 June 2026 · filed 15 June 2026
- was granted 64,988 shares of Takeda Pharmaceutical CoSEC Form 428 April 2026American Depositary Shares · traded 27 April 2026 · filed 28 April 2026
- was granted 29,000 shares of Aura Biosciences (a derivative holding)SEC Form 42 April 2025Stock Option (Right to Buy) · traded 31 March 2025 · filed 2 April 2025
- was granted 21,000 shares of Aura BiosciencesSEC Form 42 April 2025Common Stock · traded 31 March 2025 · filed 2 April 2025
- returned to the issuer 34,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 44 June 2024Stock Option (Right to Buy) · traded 4 June 2024 · filed 4 June 2024
- was granted 34,000 shares of Fusion Pharmaceuticals (a derivative holding)SEC Form 416 October 2023Stock Option (Right to Buy) · traded 16 October 2023 · filed 16 October 2023
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.